Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Allosteric therapy targets common genetic cause of Parkinson’
Drug Discovery World
Related Posts
Post navigation
Previous Post
Dosing Underway for Phase 1 Parkinson Trial of GBA1-Targeting Agent GT-02287
Next Post
The Potential of Neurofilament Light Chain as a Biomarker in Parkinson’s Disease
Latest Articles
Clear Filters
June 25, 2024
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Read More
March 27, 2022
2022 Glycolipid and Sphingolipid Biology GRC
Read More
April 27, 2021
Direct Listing vs. IPO
Read More
Close
